Trump Administration Launches TrumpRx Platform with Pfizer Deal

The Trump administration is launching TrumpRx, a direct-to-consumer marketplace that allows Americans to purchase prescription medications directly through the government at discounted prices, bypassing traditional insurance channels. The White House has announced a landmark deal with Pfizer as the platform's first pharmaceutical partner, marking a significant shift in how prescription drugs may be distributed and priced in the United States.

The federal government will operate the TrumpRx marketplace, which enables individuals to pay cash for certain drugs at prices negotiated directly by the government. The platform represents a new model for pharmaceutical purchasing, removing intermediaries and creating a direct line between government-negotiated pricing and consumers.

Under the agreement with Pfizer, drug prices will align with the lowest rates paid by other developed nations, implementing a most-favored-nation pricing structure. "The agreement will provide every State Medicaid program in the country access to MFN [most-favored-nation] drug prices on Pfizer products, resulting in many millions of dollars in savings and continuing President Trump's historic efforts to strengthen the program for the most vulnerable," the White House said.

The deal includes substantial discounts on several key Pfizer medications. Eucrisa, a topical ointment for atopic dermatitis, will be available at an 80% discount when purchased directly. Xeljanz, an oral medication for rheumatoid arthritis, psoriatic arthritis and ulcerative colitis, will be offered at a 40% discount, while Zavzpret, a migraine treatment, will be sold at a 50% discount to consumers buying through the platform.

A significant component of the agreement addresses trade policy. Pfizer will receive a three-year exemption from Trump's tariffs on pharmaceutical drugs manufactured overseas, which are scheduled to take effect October 1. In exchange, Pfizer must offer deep discounts when selling directly to American patients. "The agreement requires Pfizer to repatriate increased foreign revenue on existing products that Pfizer realizes as a result of the President's strong America First U.S. trade policies for the benefit of American patients," the White House said.

The initiative follows a July letter from President Trump to 17 pharmaceutical companies demanding reduced drug prices, with a September 29 deadline for responses. The White House has indicated it expects other pharmaceutical manufacturers to enter similar agreements following Pfizer's lead.

Click here for the original news story.